PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of casLink to Publisher's site
 
Cancer Sci. 2017 August; 108(8): 1534.
Published online 2017 August 3. doi:  10.1111/cas.13048
PMCID: PMC5543462

In This Issue

Characterization of V‐set and immunoglobulin domain cotaining 1 exerting a tumor suppressor function in gastric, lung, and esophageal cancer cells

Page 1701–14

An external file that holds a picture, illustration, etc.
Object name is CAS-108-1534-g001.jpg

Page 1701–14

Cell adhesion molecules modulate or associate with diverse signal transduction pathways and play an important role in cancer cell biology. V‐set and immunoglobulin domain containing 1 (VSIG1) is a newly discovered member of the immunoglobulin superfamily proteins, whose role in cancer biology remains unknown. In this study, Inoue et al. investigated VSIG1 expression in 11 cancers and assessed its prognostic value in patients with gastric and non‐small‐cell lung cancer. While the underlying mechanisms of tumor suppression remain unknown, their investigation assessed the effect of VSIG1 expression changes in cancer cells, specifically demonstrating that overexpression reduces cell proliferation, migration and invasion abilities while verifying that VISG1 positivity is an independent and favorable prognostic factor in gastric cancer patients.doi: 10.1111/cas.13295

Development of protein degradation inducers of oncogenic BCR‐ABL protein by conjugation of ABL kinase inhibitors and IAP ligands

Page 1657–66

An external file that holds a picture, illustration, etc.
Object name is CAS-108-1534-g002.jpg

Page 1657–66

Chronic myelogenous leukemia (CML) is a myeloproliferative disorder characterized by the Philadelphia chromosome. While several small molecule tyrosine kinase inhibitors have been developed for treatment, a significant number of patients continue to develop resistance to these drugs through point mutations in the tyrosine kinase domain of the BCR‐ABL protein. In this study, Shibata et al explored an alternative approach to CML treatment through the downregulation of the BCR‐ABL protein itself, devising a protein knockdown system by hybrid molecules named SNIPERs. These molecules, designed to induce IAP‐mediated ubiquitylation and proteasomal degradation of target proteins, were tested in various combinations and resulted in the formation of SNIPER(ABL)‐39, a molecule with potent degradation activity against the BCR‐ABL protein. This investigation suggests a possible lead for novel degradation‐based anti‐cancer drugs against BCR‐ABL‐positive CML and the key to overcoming drug resistance against kinase inhibitors.doi: 10.1111/cas.13284

Upregulation of ASAP3 contributes to colorectal carcinogenesis and indicates poor survival outcome

Page 1544–55

An external file that holds a picture, illustration, etc.
Object name is CAS-108-1534-g003.jpg

Page 1544–55

Colorectal cancer is a leading cause of morbidity and mortality worldwide. Unfortunately, many patients are diagnosed with advanced stage disease, which has resulted in an urgent need to identify targets that would be beneficial for diagnosis and treatment. Previous research has demonstrated the expression of ASAP3 in multiple tumors; however, its biological function and clinical implication in colorectal cancer remains poorly understood. Tian et al. discuss their findings, which suggest that ASAP3 plays a pivotal role in colonic carcinogenesis through its association with constitutively activated NF‐κB and demonstrates that its upregulation is associated with a poorer prognosis. This investigation suggests that ASAP3 might be a promising prognostic marker and therapeutic target in colorectal carcinoma.doi: 10.1111/cas.13281


Articles from Cancer Science are provided here courtesy of Wiley-Blackwell